This is a transformative technology that is going to disrupt the market. I am excited about working with plastic surgeons globally on Motiva, and also about bringing these new technologies and implants to the community of plastic surgeons and patients.
New York, NY (PRWEB) January 25, 2016
Establishment Labs, a global next generation breast implant and medical technology company, announced today that Dr. Scott L.Spear has joined its Medical Advisory Board.
"We are partnering with the best minds in plastic surgery to bring the latest technological innovations in breast implants to the United States market. The appointment of Dr. Spear is a clear indication of this strategy. We are honored to have a plastic surgeon of his stature joining our Medical Advisory Board," said Juan Jose Chacon Quiros, CEO of Establishment Labs.
“Dr. Spear’s leadership and expertise will be instrumental in working with doctors in the 46 countries where surgeons currently use or are switching to Motiva. With best practices and Motiva next generation technologies, we can improve patient outcomes and vastly reduce complication rates.”
Between 1992 and 2015, Dr. Scott Spear served, at different times, as Director, Chief and Chairman of the Department of Plastic Surgery at the Georgetown University School of Medicine. Dr. Scott Spear is the author of more than 130 peer-reviewed articles in scientific journals and has collaborated on over 200 chapters and 3 books on Plastic and Reconstructive Surgery. Before resigning in December 2015, Dr. Spear also served as the Chairman of the Plastic Surgery Executive Council at Allergan Inc.
Dr. Spear commented, "For some time, I have been thinking about the high rates of some complications associated with breast implants, and how we should endeavor to radically reduce these rates. Establishment Labs shares that goal, and it is a pleasure for me to support their work and help them to continue their culture of innovation.”
“Today, the vast majority of implants sold are based on our 1992 understanding of how the body reacts to breast implants and silicone. Motiva products are truly innovative, designed with the latest understanding of materials sciences, surface technology, and physiology. This is a transformative technology that is going to disrupt the market. I am excited about working with plastic surgeons globally on Motiva, and also about bringing these new technologies and implants to the community of plastic surgeons and patients in the United States.”
Dr. Spear concluded, “I believe that the safety profile of the Generation 3 Motiva implant is superior to any other breast implant on the market today and that our continued innovation will change how both doctors and women think about implants and improve the health of women worldwide.”
Rudy Mazzocchi, Executive Chairman of Establishment Labs added, "The support of distinguished medical leaders such as Dr. Spear is a testament to the importance of what Establishment Labs is accomplishing with innovations that improve the health and safety standards for women around the world.”
Establishment Labs is currently building a second, state of the art manufacturing facility to support increased demand for its products and the beginning of the approval process in the United States for its innovative line of Motiva silicone breast implants in 2016.
About Establishment Labs:
Establishment Labs is a global, privately held, surgical aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (http://www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC.